Who are oxaliplatin and gemcitabine's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): gemcitabine/Eloxatin (GEMOX).

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/oxaliplatin-and-gemcitabine.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

oxaliplatin and gemcitabine — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

oxaliplatin and gemcitabine (oxaliplatin and gemcitabine) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Platinum-based chemotherapeutic agent and nucleoside analog. Area: Oncology.

phase 3 Platinum-based chemotherapeutic agent and nucleoside analog Oncology Small molecule Live · refreshed every 30 min

Target snapshot

oxaliplatin and gemcitabine (oxaliplatin and gemcitabine) — Shanghai Zhongshan Hospital. Oxaliplatin works by forming platinum-DNA adducts, which interfere with DNA replication and transcription, leading to cell death. Gemcitabine is a nucleoside analog that inhibits DNA synthesis by causing DNA strand breaks.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
oxaliplatin and gemcitabine TARGET	oxaliplatin and gemcitabine	Shanghai Zhongshan Hospital	phase 3	Platinum-based chemotherapeutic agent and nucleoside analog
gemcitabine/Eloxatin (GEMOX)	gemcitabine/Eloxatin (GEMOX)	Sanofi	phase 3	platinum-based chemotherapeutic agent and nucleoside analog

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Platinum-based chemotherapeutic agent and nucleoside analog class)

Shanghai Zhongshan Hospital · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). oxaliplatin and gemcitabine — Competitive Intelligence Brief. https://druglandscape.com/ci/oxaliplatin-and-gemcitabine. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab